Discovers and develops innovative medicines. Focuses on areas of unmet medical need. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 14% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $164.1M against $55.2M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, NKTR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NKTR’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.